Cargando…

Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study

BACKGROUND: Monoclonal antibodies are a treatment option for patients with mild-to-moderate coronavirus disease (COVID-19). We investigated the effectiveness of regdanvimab, an anti-severe acute respiratory syndrome coronavirus-2 monoclonal antibody approved in Korea, in the treatment of patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Seong Jin, Park, Sang-Won, Lee, Eunyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987185/ https://www.ncbi.nlm.nih.gov/pubmed/35384421 http://dx.doi.org/10.3947/ic.2021.0140

Ejemplares similares

Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak
por: Lee, Chan Mi, et al.
Publicado: (2022)

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
por: Park, Susin, et al.
Publicado: (2022)

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022)

Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
por: Noh, Hyeong-Jun, et al.
Publicado: (2023)

Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
por: Jang, Young Rock, et al.
Publicado: (2023)

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
por: Kim, Taeyun, et al.
Publicado: (2022)

Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study
por: Lee, Shinwon, et al.
Publicado: (2022)

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
por: Kim, Jin Yong, et al.
Publicado: (2022)

Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Publicado: (2023)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Regdanvimab Treatment of COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
por: Hong, Sun In, et al.
Publicado: (2022)

546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial
por: Ison, Michael G, et al.
Publicado: (2021)

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
por: Lee, Ji Yeon, et al.
Publicado: (2021)

The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
por: Chae, Ganghee, et al.
Publicado: (2022)

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
por: Lee, Ji Yeon, et al.
Publicado: (2023)

Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
por: Kwak, Yee Gyung, et al.
Publicado: (2022)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022)

The Impact of Wearing a Mask on Oxygenation and Hemodynamics in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease
por: Kim, Sang-Heon, et al.
Publicado: (2023)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
por: Marcec, Robert, et al.
Publicado: (2023)

Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
por: McSweeney, Morgan D., et al.
Publicado: (2022)

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer’s dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial
por: Park, Kyung Won, et al.
Publicado: (2017)

Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
por: Kim, Haein, et al.
Publicado: (2023)

The need for a correct oxygen-ozone autohemotherapy (O(3)-AHT) in patients with mild to moderate COVID-19 pneumonia
por: Chirumbolo, Salvatore, et al.
Publicado: (2021)

Clinical Predictors for Mild Cognitive Impairment Progression in a Korean Cohort
por: Shim, Yong S., et al.
Publicado: (2016)

Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
por: Maynard, Steven Douglas, et al.
Publicado: (2013)

Risk factors associated with the need for oxygen therapy in patients with COVID-19
por: Noh, Chang Suk, et al.
Publicado: (2021)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

Kidney manifestations of mild, moderate and severe coronavirus disease 2019: a retrospective cohort study
por: Hong, Daqing, et al.
Publicado: (2020)

Unmet Needs and Behavioral Expressions: The Perspective of Individuals with Mild to Moderate Dementia
por: Minyo, Morgan, et al.
Publicado: (2020)

Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs
por: Castaman, Giancarlo, et al.
Publicado: (2023)

Digital Health Interventions in Prevention, Relapse, and Therapy of Mild and Moderate Depression: Scoping Review
por: Tokgöz, Pinar, et al.
Publicado: (2021)

Clinical Characteristics of COVID-19: Risk Factors for Early Oxygen Requirement after Hospitalization
por: Suh, Hyeon Jeong, et al.
Publicado: (2021)

Bioresonance, an alternative therapy for mild and moderate depression
por: Muresan, Daniela, et al.
Publicado: (2022)

Clinical Assessment of the Hyperbaric Oxygen Therapy Efficacy in Mild to Moderate Periodontal Affections: A Simple Randomised Trial
por: Burcea, Alexandru, et al.
Publicado: (2022)

Moderate vs. mild cases of overseas-imported COVID-19 in Beijing: a retrospective cohort study
por: Zhai, Wenliang, et al.
Publicado: (2021)

Hydrothermotherapy in prevention and treatment of mild to moderate cases of COVID-19
por: Ramirez, Francisco E., et al.
Publicado: (2021)

Bariatric surgery versus conventional therapy in obese Korea patients: a multicenter retrospective cohort study
por: Heo, Yoon-Seok, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e0kl2hpi5lqkvaj63qep9pgmk6